{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["86(1)"],"submitter":["Nagard M"],"funding":["Cancer Research UK","National Institute for Health Research (NIHR)","AstraZeneca"],"pubmed_abstract":["<h4>Purpose</h4>To support future dosing recommendations, the effect of food on the pharmacokinetics of adavosertib, a first-in-class, small-molecule reversible inhibitor of WEE1 kinase, was assessed in patients with advanced solid tumors.<h4>Methods</h4>In this Phase I, open-label, randomized, two-period, two-sequence crossover study, the pharmacokinetics of a single 300 mg adavosertib dose were investigated in fed versus fasted states.<h4>Results</h4>Compared with the fasted state, a high-fat, high-calorie meal (fed state) decreased adavosertib maximum plasma concentration (C<sub>max</sub>) by 16% and systemic exposure (area under the plasma concentration-time curve [AUC]) by 6%; AUC<sub>0-t</sub> decreased by 7% and time to maximum plasma concentration was delayed by 1.97 h (P = 0.0009)"],"journal":["Cancer chemotherapy and pharmacology"],"pagination":["97-108"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7338825"],"repository":["biostudies-literature"],"pubmed_title":["Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors."],"pmcid":["PMC7338825"],"pubmed_authors":["Ah-See ML","So K","Vermunt M","Campone M","Ottesen L","Roxburgh P","Nagard M","Ravaud A","Labots M","Valkenburg-van Iersel L","Li Y","Mugundu G","Thistlethwaite F"],"additional_accession":[]},"is_claimable":false,"name":"Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors.","description":"<h4>Purpose</h4>To support future dosing recommendations, the effect of food on the pharmacokinetics of adavosertib, a first-in-class, small-molecule reversible inhibitor of WEE1 kinase, was assessed in patients with advanced solid tumors.<h4>Methods</h4>In this Phase I, open-label, randomized, two-period, two-sequence crossover study, the pharmacokinetics of a single 300 mg adavosertib dose were investigated in fed versus fasted states.<h4>Results</h4>Compared with the fasted state, a high-fat, high-calorie meal (fed state) decreased adavosertib maximum plasma concentration (C<sub>max</sub>) by 16% and systemic exposure (area under the plasma concentration-time curve [AUC]) by 6%; AUC<sub>0-t</sub> decreased by 7% and time to maximum plasma concentration was delayed by 1.97 h (P = 0.0009)","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jul","modification":"2026-07-15T23:35:00.916Z","creation":"2025-04-06T12:38:14.141Z"},"accession":"S-EPMC7338825","cross_references":{"pubmed":["32556602"],"doi":["10.1007/s00280-020-04101-4"]}}